Panacea Biotec Ltd.
Snapshot View

121.55 -4.05 ▼-3.2%

03 February 2023, 04:01:00 PM
Volume: 16,718

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.panaceabiotec.com
Market Cap 746.03 Cr.
Enterprise Value(EV) 492.69 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 187.40 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 0.65 Trailing Twelve Months Ending 2022-09
Industry PE 32.22 Trailing Twelve Months Ending 2022-09
Book Value / Share 131.94 Trailing Twelve Months Ending 2022-09
Price to Book Value 0.92 Calculated using Price: 121.55
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 6.13 Cr. 61,250,746 Shares
FaceValue 1
Company Profile
The company has product portfolio that's caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal. Business Areas of the Company :- (1) Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). (2) Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. (3) Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-3.22%
1 Week
-4.67%
1 Month
-14.13%
3 Month
-14.01%
6 Month
-13.61%
1 Year
-51.51%
2 Year
-44.00%
5 Year
-56.08%
10 Year
-6.03%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -76.49 -253.03 -34.38 -22.94 11.39 -75.26 347.66
Return on Capital Employed (%) 3.37 0.45 9.93 2.76 2.63 13.44 -0.38 5.36 221.15
Return on Assets (%) -5.47 -4.87 -1.01 -2.97 -4.53 2.55 -13.36 -10.69 73.58

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 513 471 449 356 309 350 199 -229 849 808
Non Curr. Liab. 767 918 1,100 719 591 70 741 960 104 118
Curr. Liab. 827 706 475 689 696 938 622 449 803 410
Minority Int. 5 3 1 11 -3 -3 -3 -3 -3 -3
Equity & Liab. 2,112 2,099 2,025 1,774 1,592 1,356 1,559 1,177 1,752 1,333
Non Curr. Assets 1,739 1,573 1,475 1,071 1,028 848 875 666 712 664
Curr. Assets 373 526 549 703 565 508 683 511 1,041 670
Misc. Exp. not W/O
Total Assets 2,112 2,099 2,025 1,774 1,592 1,356 1,559 1,177 1,752 1,333

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 510 687 653 544 593 457 544 625 661 512
Other Income 15 28 20 47 8 5 30 10 11 28
Total Income 525 716 673 591 601 462 574 635 672 541
Total Expenditure -592 -643 -541 -497 -508 -590 -519 -548 -675 -614
PBIDT -67 72 132 94 93 -128 56 87 -3 -74
Interest -150 -105 -127 -101 -101 -105 -174 -185 -181 -85
Depreciation -71 -67 -73 -68 -59 -55 -44 -46 -44 -42
Taxation -2 -3 -2 11 -10 -9 -17 -2 -371 -383
Exceptional Items 177 50 8 334 -15 1,676 1,732
PAT -113 -102 -21 -56 -76 38 -195 -146 1,078 1,148
Minority Interest 1 2 2 2 2 0 0 0 0
Share Associate -1 -6 0 0 0 0 0
Other Related Items
Consolidated Net Profit -112 -107 -18 -54 -74 38 -194 -148 1,078 1,148
Adjusted EPS -18 -17 -3 -9 -12 6 -32 -24 176 187

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -24 54 37 91 131 118 105 -30 107 -108
Cash Fr. Inv. -61 -38 -37 16 -26 55 -5 -35 -48 1,283
Cash Fr. Finan. 105 -30 -1 -117 -107 -164 -101 91 -47 -1,176
Net Change 20 -14 -1 -10 -2 9 -2 26 12 -2
Cash & Cash Eqvt 35 21 20 10 7 16 14 40 52 50

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59
Public 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 69.36 94.27 94.27 94.27 94.27 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 01 Feb 2023
Board Meeting Intimation for Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And NineMonths Ended December 31 2022
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2022.With reference to our earlier announcement dated December 29 2022 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16 2023and the same will re-open from February 17 2023.
Tue, 17 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Panacea Biotec Ltd. has on humanitarian grounds donated 125 000 single dose vials (SDVs) of its WHO Prequalified Pentavalent vaccine Easyfive- IT to the Ministry of Health ofRepublic of Cuba for use in Cuba National Health System specifically in the expanded immunization program due to current ongoing shortage of the wP based Pentavalent Vaccine in Cuba.A copy of the Press Release being issued to the media etc. in this regard is enclosed.
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
We are enclosing herewith a certificate dated January 04 2023 issued by Skyline Financial Services Private Limited Registrar and Transfer Agent of the Company confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022.

Technical Scans View Details >>

Fri, 03 Feb 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Low Close Crossing Last Month Low

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 246,567.66 1,027.65 +2.0%
Cipla Ltd. 82,812.97 1,026.00 +0.1%
Divi's Laboratories Ltd. 76,573.08 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. 72,577.66 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. 61,039.46 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. 52,289.82 1,545.00 +0.3%
Abbott India Ltd. 44,198.55 20,800.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 58.54 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 31.39 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 25.59 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.92 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.70 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.92 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 50.12 20,800.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.46 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 3.65 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 6.31 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.30 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.20 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 16.28 20,800.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 0.04 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 0.00 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,800.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 798.70 20,800.00 +1.5%

FAQ's On Panacea Biotec Ltd.

What is Panacea Biotec share price?

Can I buy Panacea Biotec shares now?

What is the Market Cap of Panacea Biotec?

What are the key metrics to analyse Panacea Biotec?

What is the 52 Week High and Low of Panacea Biotec?

What is the trend of Panacea Biotec share price?